

7th Annual Innovative Approaches to Brain Tumor Management - VIRTUAL
Friday, February 11, 2022

AGENDA

- 7:55 a.m. Welcome & Announcements**
Charles Cobbs, M.D. & Zachary N. Litvack, M.D.
- 8 a.m. TBD**
Kester Phillips, M.D.
Objectives:
- 8:15 a.m. Q&A**
- 8:20 a.m. Transiently Opening the Blood-Brain Barrier to Treat Malignancies: Challenges and Opportunities**
Matthew Smith-Cohn, D.O.
Objectives:
- Outline the challenges the blood-brain barrier poses in treating primary and secondary malignancies to the brain
 - Review treatment approaches being studied to transiently open the blood-brain barrier to increase drug delivery
- 8:35 a.m. Q&A**
- 8:40 a.m. Molecular Evaluation & Treatment of Gliomas**
Howard Colman, M.D.
Objectives:
- Identify and apply recent changes in glioma molecular characterization based on cIMPACT and WHO 2021 criteria
 - Describe the relationship between integrated histological/molecular diagnosis and appropriate therapy for gliomas
- 9:05 a.m. Q&A**
- 9:10 a.m. Primary CNS Lymphoma: An Overview of Management & Highlight of Advances**
Joe Mendez, M.D.
Objectives:
- Describe the initial evaluation/work-up of a patient with suspected newly diagnosed Primary CNS Lymphoma (PCNSL)
 - a. Identify how to outline the work up to evaluate for the extent of CNS involvement
 - b. Identify how to outline the work up to evaluate for systemic involvement
 - Identify familiarities with the commonly used induction and consolidation therapies used to treat PCNSL
 - Discuss familiarities with the role of targeted therapy and immunotherapy in PCNSL

- 9:25 a.m. Q&A
- 9:30 a.m. **Update of Imaging in Brain Tumors**
David Olayinka Kamson, M.D., PhD
Objectives:
- 9:45 a.m. Q&A
- 9:50 a.m. **Clinical and Molecular Determinants of Outcome for Non-Optic Pathway Gliomas in Adults with Neurofibromatosis Type 1**
Carlos Guillermo Romo, M.D.
Objectives:
- Outline the difference in clinical and molecular features of gliomas in people with NF1 compared to sporadic cases
 - Identify the treatment options and outcomes for adults with NF1 and a non-optic pathway glioma
- 10:05 a.m. Q&A
- 10:10 a.m. **Update on Immunotherapy of Gliomas**
Michael Lim, M.D.
Objectives:
- Describe the current state of immunotherapy for brain tumors
 - Identify the strategies to overcome glioma induced immunosuppression
- 10:25 a.m. Q&A
- 10:30 a.m. **Multi-omic analysis of GBM tissues treated with neoadjuvant anti-PD1 therapy at recurrence reveals candidates for combination checkpoint immunotherapy**
Jim Heath, Ph.D.
Objectives:
- Outline how the cellular microenvironment of the tumor can be characterized
 - Describe how that characterization provides hypotheses for drug targets
 - Identify major differences between the microenvironment of melanoma tumors relative to GBM tumors
- 10:45 a.m. Q&A
- 10:50 a.m. **Targeting Cancer Stem Cells for Treatment of Glioblastoma**
Parvinder Hothi, Ph.D. (pre-recorded)
Objectives:
- Outline the role of cancer stem-like cells in glioblastomas
 - Outline the methods for culturing and viable storage of tumor stem cells
 - Explain the use of high-throughput drug screening in devising personalized treatments
- 11:05 a.m. Q&A
- 11:25 a.m. TBD
TBD
Objectives:

- 11:40 a.m. Q&A**
- 11:45 a.m. Incorporation of BRAF – targeted therapy Into Neuro-Oncology Clinical Practice**
Karisa Schreck, M.D.
Objectives:
- Recognize molecular alterations for which BRAF – targeted therapy might be efficacious
 - Identify appropriate small molecule targeted therapy of clinical trials for an individual patient
 - Recognize toxicities of RAF – targeted therapy
- 12 p.m. Q&A**
- 12:05 p.m. TBD**
Charles Cobbs, M.D.
Objectives:
- 12:20 p.m. Q&A**
- 12:25 p.m. TBD**
Zachary Litvack, M.D.
Objectives:
- 12:40 p.m. Q&A**
- 12:45 p.m. The 2021 WHO Classification of Tumors of the CNS (WHO CNS5)**
Daniel Brown, M.D., MBA
Objectives:
- Outline both the major general changes as well as the specific changes in the more common taxonomic tumor categories.
 - Understand the developments that are advancing the role of molecular diagnostics in CNS tumor classification.
 - Recognize shifting approaches to CNS nomenclature and grading emphasizing the importance of integrated diagnoses and layered reports.
- 1 p.m. Q&A**
- 1:05 p.m. Proton Therapy for Leptomeningeal Disease**
Lia Moriguchi Halasz, M.D.
Objectives:
- Explain how proton therapy may improve the therapeutic index for patients with leptomeningeal disease
 - Examine published data on craniospinal irradiation for leptomeningeal metastases
 - Explore future directions in proton therapy for leptomeningeal disease
- 1:20 p.m. Q&A**

1:25 p.m. Survivorship Care in Neuro-Oncology

Akanksha Sharma, M.D.

Objectives:

- Review the importance of survivorship care for patients with brain tumors and their loved ones, emphasizing its unique place in cancer care.
- Explain the key areas of importance as it applies to survivorship care for this patient population and the existing evidence on management for each.
- Identify existing models of survivorship programs in neuro-oncology and a potential framework for the development of these programs at brain tumor centers.

1:40 p.m. Q&A

1:45 p.m. Adjourn

ESTEEMED FACULTY

Charles Cobbs, M.D.

Course Co-Chair
Director, Ben & Catherine Ivy Center
Swedish Neuroscience Institute
Seattle, Washington

Zachary N. Litvack, M.D., FAANS, FACS

Course Co-Chair
Director, Skull Base & Minimally Invasive
Neurosurgery
Swedish Neuroscience Institute
Seattle, Washington

Kester Phillips, M.D.

Course Co-Chair
Neuro-oncologist
Ben & Catherine Ivy Center
Seattle, Washington

Matthew Smith-Cohn, D.O.

Course Co-Chair
Neuro-oncologist
Ben & Catherine Ivy Center
Seattle, Washington

Daniel Brown, M.D., MBA

Chair, Department of Pathology & Laboratory
Medicine
Chief, Section of Neuropathology
Medical Director NHL Lab Medicine
Lehigh Valley Health Network
Allentown, PA

Howard Colman, M.D., Ph.D.

Leader of Center for Neurologic Cancer
Huntsman Cancer Institute
Salt Lake City, Utah

Lia Moriguchi Halasz, M.D.

Associate Professor & Residency Director of
Department of Radiation Oncology
Joint Associate Professor Department of
Neurological Surgery
Co-Director Alvord Brain Tumor Center
Attending Physician UW Medical Center, SCCA
Proton Therapy Center & Harborview Medical
Center

Jim Heath, Ph.D.

President Institute for Systems Biology
Institute Systems Biology
Seattle, Washington

Parvinder Hothi, Ph.D.

Head Lab Scientist
Ben & Catherine Ivy Center
Swedish Neuroscience Institute
Seattle, Washington

David Olayinka Kamson, M.D., Ph.D.

Assistant Professor of Neurology
Department of Neuro-Oncology
Johns Hopkins Medicine
Baltimore, Maryland

Michael Lim, M.D.

Chair of Neurosurgery
Stanford Hospital
Palo Alto, California

Joe Mendez, M.D.

Assistant Professor of Neurosurgery
University of Utah & Huntsman Cancer Institute
Salt Lake City, Utah

Carlos Guillermo Romo, M.D.

Assistant Professor of Neurology
Johns Hopkins Hospital
Baltimore, Maryland

Akanksha Sharma, M.D.

Assistant Professor Neuro-Oncology Translational
Neurosciences
Providence Saint John's Health Center
Santa Monica, California

Karisa Shreck, M.D., Ph.D.
Assistant Professor of Neurology
The Johns Hopkins Hospital
Baltimore, Maryland

Brain Tumor Agenda 2022 V13 .docx